Piracetam Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: Piracetam evidence and protocol review

Nootropic Compounds compound PowderCapsule verified

Also known as: 2-oxo-1-pyrrolidine acetamide

Open in Calculator ← Compound Index All Tools

Quick Facts

Reference Sizes

10 g, 100 g

Storage

Follow jurisdiction- and formulation-specific medicinal-product labeling; RUO powder needs lot-specific documentation

Solubility

Highly water-soluble

Catalog Description

Piracetam is the original racetam compound (first synthesized 1964), studied for cholinergic and glutamatergic neurotransmission modulation, weak AMPA receptor (ampakine) activity, improved membrane fluidity, and enhanced cerebral blood flow. Despite six decades of research its precise mechanism of action remains only partially characterized, and racetams are noted to have multiple modes of action. Early clinical trials in dementia and cognitive impairment suggested modest benefit, but methodological weaknesses led to cautious Cochrane-review conclusions; a 2024 meta-analysis of 18 studies (886 patients) found no clinically meaningful difference in memory enhancement versus control in adults. Reported safety profile is favorable at commonly studied doses (up to 12g/day for 8 weeks).

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life

Common clinical pharmacokinetic estimates are formulation- and renal-function dependent; use study or product-specific data rather than a universal RUO value

Onset

Clinical trials have typically assessed cognitive outcomes over weeks to months

Administration Routes (Research)

IV and oral in indication-specific human trials

Reported Research Effects

Weak AMPA receptor (ampakine) modulation
Cholinergic/glutamatergic neurotransmission modulation
2024 meta-analysis: no clinically meaningful memory benefit vs. control in adults

Reported Research Side Effects

CNS stimulation, aggressiveness, agitation, irritability, poor sleep, decreased appetite, and sexual arousal were reported in a pediatric Down-syndrome trial
Stroke trial showed no overall benefit and numerically higher mortality that was not statistically significant
Renal clearance makes kidney function relevant

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

12 g IV loading dose, then 12 g/day for 4 weeks and 4.8 g/day for 8 weeks [IV then oral/systemic study regimen; Randomized acute ischemic-stroke trial; Daily]Source: PMID 9412612; primary outcome was neutral in the full population
2.4 g twice daily for 6 weeks with intensive speech therapy [Oral; Double-blind post-stroke aphasia study; Twice daily]Source: PMID 10978039
4.8 g/day for 6 months [Oral; Randomized post-stroke aphasia study; Divided daily dosing]Source: PMID 21227483; no clear overall language benefit
7.2 g/day for 2 weeks then 4.8 g/day through the study [Oral; Randomized ECT cognitive-adverse-effect prevention study; Daily]Source: PMID 12394531; no significant prevention effect

Research Notes

The catalog now includes tested high-dose clinical schedules and their neutral or mixed findings. These are disease-specific research regimens, not healthy-person nootropic guidance.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

Piracetam Acute Stroke Study — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/9412612/

Piracetam post-stroke aphasia PET trial — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/10978039/

Piracetam six-month post-stroke aphasia trial — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/21227483/

Piracetam ECT cognitive-effects randomized trial — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/12394531/

Piracetam memory systematic review and meta-analysis — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/38878641/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.